A Chinese biopharmaceutical firm has sealed a global licensing deal valued at up to US$1.44 billion, the second in a week, as a wave of cross-border tie-ups shows no sign of abating despite headwinds from the US Biosecure Act.
Shanghai Scizeng Medical Technology, a unit of Changchun High-Tech Industry, has agreed to grant US-based Yarrow Bioscience exclusive global rights to develop, manufacture and commercialise GenSci098, an injectable therapy for thyroid eye disease and Graves’ disease, both…
